Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline for Negative Symptoms in Schizophrenia
NCT00492336Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2007
- Primary completion
- Feb 2012
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rasagiline in schizophrenia (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Change in Negative Symptoms (SANS) at 12 weeks, Repeatable Battery for the Assessment of Neuropsychological Status Total Score at 12 weeks and 3 more. Started Jan 2007; status: completed.
02
Drugs
rasagiline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00492336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492336.